PRAD and BLCA are primarily related to the regulation of androgens and their receptors [28–30], and inhibiting androgen receptor signaling and androgen deprivation therapy are well established to restrain tumor cell biological behaviors and provide patients with benefits in prolonging the recurrence period [31, 32]. The gene discussed is AR; the disease is bladder transitional cell carcinoma.